Millennium Management’s Ibere Pharmaceuticals IBER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-114,500
Closed -$23K 7767
2022
Q1
$23K Sell
114,500
-97,500
-46% -$950K ﹤0.01% 6615
2021
Q4
$114K Buy
212,000
+62,500
+42% +$608K ﹤0.01% 6201
2021
Q3
$89K Buy
149,500
+52,000
+53% +$503K ﹤0.01% 6475
2021
Q2
$74K Buy
+97,500
New +$949K ﹤0.01% 6314

Millennium Management's IBER Position: Q1 2023 in Review

Millennium Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 660,664 shares — an estimated $6.67M sold.

Millennium Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $6.67M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

  • Millennium Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Millennium Management sold 660,664 Ibere Pharmaceuticals shares in Q1 2023, an estimated $6.67M.
  • Millennium Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Millennium Management's Ibere Pharmaceuticals position peaked at $6.67M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.